Learn more at LeadIQ.com

Insights

Gathering insights about Abivax…

Similar companies to Abivax

Abivax Tech Stack

Abivax uses 8 technology products and services including jsDelivr, Unpkg, Joomla, and more. Explore Abivax's tech stack below.

jsDelivr
Content Delivery Network
Unpkg
Content Delivery Network
Joomla
Content Management System
GSAP
Javascript Frameworks
React
Javascript Frameworks
AOS
Javascript Libraries
Modernizr
Javascript Libraries
Module Federation
Miscellaneous

Media & News

Abivax SA hired Ana Sharma as Vice President, Global Head of Quality on Feb 7th '24.
Abivax appoints Ana Sharma as Vice President, Global Head of Quality
Feb 06, 2024 | www.francedailytimes.com
Abivax SA received financing of $541M in financing on Jan 1st '23.
Abivax has secured more than EUR 500M financing in 2023 and we expect to have sufficient funds to finance our operations into Q4 2025, including through the anticipated release of top-line Phase 3 induction data from the ABTECT program.
Feb 03, 2024 | www.sharewise.com
Abivax SA hires Michael Ferguson as chief commercial officer.
French immunology company Abivax has appointed Michael Ferguson as its new chief commercial officer (CCO).
Jan 21, 2024 | www.thepharmaletter.com
Abivax SA invested into assets: property, plant, equipment in the amount of $233K on Dec 1st '23.
For the six months ended in Dec. 2023, Abivax spent €0.21 Mil on purchasing property, plant, equipment.
Dec 01, 2023 | www.gurufocus.com
Abivax SA went public on Jan 1st '23.
Abivax adss slide in trading debut after U.S. IPO priced at low end.
Oct 19, 2023 | www.marketwatch.com
Abivax SA went public on Sep 29th '23.
Genetic medicines biotech Lexeo Therapeutics and immune-focused French company Abivax both filed for their initial public offerings on Friday.
Sep 30, 2023 | www.biospace.com
Abivax SA launches 2023 half-year financial report.
PARIS, France, September 29, 2023 - 6:00 p.m. (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announces today the release of its 2023 half-year financial report.
Sep 28, 2023 | ir.abivax.com

Abivax's Email Address Formats

Abivax uses at least 1 format(s):

Abivax Email Formats	Example	Percentage
First.Last@abivax.com	John.Doe@abivax.com	96%
FLast@abivax.com	JDoe@abivax.com	2%
First.MiddleLast@abivax.com	John.MichaelDoe@abivax.com	1%
First.L@abivax.com	John.D@abivax.com	1%

Frequently Asked Questions

Where is Abivax's headquarters located?

Abivax's main headquarters is located at 7-11, Boulevard Haussmann Paris, Île-de-France 75009 FR. The company has employees across 3 continents, including EuropeNorth AmericaAsia.

What is Abivax's stock symbol?

Abivax is a publicly traded company; the company's stock symbol is ABVX.

What is Abivax's official website and social media links?

Abivax's official website is abivax.com and has social profiles on LinkedIn.

How much revenue does Abivax generate?

As of July 2024, Abivax's annual revenue reached $35M.

What is Abivax's SIC code NAICS code?

Abivax's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Abivax have currently?

As of July 2024, Abivax has approximately 81 employees across 3 continents, including EuropeNorth AmericaAsia. Key team members include Chief Executive Officer: M. D. G.Chief Business Officer: P. C.Chief Strategy Officer: D. Z.. Explore Abivax's employee directory with LeadIQ.

What industry does Abivax belong to?

Abivax operates in the Biotechnology Research industry.

What technology does Abivax use?

Abivax's tech stack includes jsDelivrUnpkgJoomlaGSAPReactAOSModernizrModule Federation.

What is Abivax's email format?

Abivax's email format typically follows the pattern of . Find more Abivax email formats with LeadIQ.

How much funding has Abivax raised to date?

As of July 2024, Abivax has raised $163M in funding. The last funding round occurred on Aug 21, 2023 for $163M.

When was Abivax founded?

Abivax was founded in 2013.

Abivax

Abivax

Biotechnology ResearchÎle-de-France, France51-200 Employees

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease.
 
Obefazimod is an investigational, orally administered, once-daily therapy, which we believe has the potential to be a differentiated treatment option for inflammatory bowel diseases. It is the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. If approved, this therapy has the potential to establish a new therapeutic class currently being referred to as miR-124 enhancers.

Company Overview

Headquarters: 7-11, Boulevard Haussmann Paris, Île-de-France 75009 FR
Website: abivax.com
SIC Code: 8733 - Noncommercial Research Organizations
Stock Symbol: ABVX
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2013
Employees: 51-200

Media & News

Funding & Financials

$163M
Abivax has raised a total of $163M of funding over 6 rounds. Their latest funding round was raised on Aug 21, 2023 in the amount of $163M.
$10M$50M
Abivax's revenue is in the range of $10M$50M

Funding & Financials

$163M
Abivax has raised a total of $163M of funding over 6 rounds. Their latest funding round was raised on Aug 21, 2023 in the amount of $163M.
$10M$50M
Abivax's revenue is in the range of $10M$50M

Company Leadership

M. D. G.
Chief Executive Officer
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
P. C.
Chief Business Officer
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
D. Z.
Chief Strategy Officer
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
D. S.
Chief Scientific Officer
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
I. H.
Chief People Officer And Chief Compliance Officer
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Employee Directory

D. S.
Chief Scientific Officer
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
I. H.
Chief People Officer And Chief Compliance Officer
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
J. S.
Chief Medical Officer Abivax Paris And Co Owner Of Maison Margiela Brussels And Swallows Sprl
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
P. P.
Chairman Of The Board
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
J. F.
Senior Vice President Evidence Generation And Heor
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Abivax and Millions of Other Companies
Sign up for full access to Abivax information. No credit card needed.
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Go to Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.